| 1006 Rec'd PCT/PTO 13 OCT 2005 | 1724616051US | October 12 00 -

F 070 4200 MOD										
Form PTO-1390-MOD  U. S. Department of Commerce Patent and Trademark Office (REV 10-96)		ATTORNEY'S DOCKET NUMBER PC/4-33172A								
TRANSMITTAL LETTER TO T	HE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
DESIGNATED/ELECTED O	FFICE (DO/EO/US)	10/552835								
CONCERNING A FILING UN	IDER 35 U.S.C. 371	-01772079								
INTERNATIONAL APPLICATION NO. PCT/EP2004/003980	INTERNATIONAL FILING DATE 15 April 2004 (15.04.04)	PRIORITY DATE CLAIMED								
TITLE OF INVENTION	13 April 2004 (13:04:04)	16 April 2003 (16.04.03)								
PROCESS FOR THE PREPARATION OF N-	SUBSTITUTED 2-CYANOPYRROL	IDINES								
APPLICANT(S) FOR DO/EO/US										
SCHAEFER ET AL.										
Applicant herewith submits to the United States De	esignated/Elected Office (DO/EO/US) th	e following items and other information:								
<ol> <li>This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority</li> </ol>										
5. A copy of the International Application as										
<ul> <li>b.</li></ul>	b. As been transmitted by the International Bureau. (See Form PCT/IB/308)									
6. A translation of the International Application	on into English (35 U.S.C. 371(c)(2)).	, ,								
7. Amendments to the claims of the Internat a.  are transmitted herewith (required	ional Application under PCT Article 19 ( I only if not transmitted by the Internatio									
b. have been transmitted by the Inte	rnational Bureau.	,								
<ul> <li>c.  have not been made; however, the</li> <li>d.  have not been made and will not</li> </ul>		ts has NOT expired.								
8. A translation of the amendments to the cla		71 (c)(3)).								
<ol><li>An executed Declaration and Power of At</li></ol>	torney (original or copy) (35 U.S.C. 371	(c)(4)).								
<ol> <li>A translation of the annexes to the Internations 371(c)(5)).</li> </ol>										
ο· .(ο)(ο)/.										
Items 11. to 16. below concern document(s) or	information included.									
11.   An Information Disclosure Statement und	er 37 CFR 1.97 and 1.98.									
12.   An assignment document for recording.	A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included.								
13. A FIRST preliminary amendment.  A SECOND or SUBSEQUENT preliminary	v amendment									
14. ⊠ An Application Data Sheet under 37 CFR										
16. A change of power of attorney and/or add										
	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.									
18. A second copy of the published Internation	A second copy of the published International Application under 35 U.S.C. 154(d)(4).									
19. A second copy of the English language tra	anslation of the International application	under 35 U.S.C. 154(d)(4).								
20.  Other items or information:										

JC20 Rec'd PCT/PTO 13 OCT 2009

U.S. APPLICATION NO	(if known, see	362	PO	ERNATIONAL APPLICATION N T/EP2004/003980	Ю.		PC/4-331	S DOCKET NUMBER			
The following fe							1 6/4 331		CULATIO	NS moure	
J								ONLY			
21. 🛭 Basi	c national	fee					\$300				
22. Examination Fee							1				
☐ If International preliminary examination report was prepared by USPTO											
and all claims satisfy provisions of PCT Article 33(1)-(4)											
All other situations											
23. Search fee							1				
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international							1				
application to the USPTO as an International Searching Authority \$  ☑ If International Search Report was prepared and provided to the Office \$400							,				
							\$				
								1			
				F 21, 22 AND 23 =				\$	900		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction											
thereof. Total Sheets	Extra	sheets	Number of e	each additional 50 or	fraction	1	RATE	T		_	
10 100		1 /22	thereof (rou	nd up to a whole num	nber)			<u> </u>			
16 - 100 =		/50 = ]		0		X \$	250	\$			
Surcharge of \$130 for furnishing the oath of declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).							\$				
CLAIMS		NUMBE	R FILED	NUMBER EXTR	A		ATE				
Total claims	•	25	- 20 =			<b>(</b> \$	50	\$	250		
Independent cla		CLAIM(S)	(if applicable		- 1 :	<u>&lt; \$</u> ⊦ \$	200 360	\$ \$	200		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =							\$	1,350			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be						<del>                                     </del>					
filed (Note 37 CFR 1.9, 1.27, 1.28).						\$	4.050				
SUBTOTAL =						\$	1,350				
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$					
TOTAL NATIONAL FEE =						\$	1,350				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied											
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +  TOTAL FEES ENCLOSED =						<b>\$</b>	1,350				
TOTAL FEES ENGLOSED =						+					
								_	mount to refunded	\$	
									charged	\$	
a. A check in the amount of \$ to cover the above fees is enclosed.											
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,350 to cover the above fees. A duplicate copy of this form is enclosed.											
c. 🗵 The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to											
Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
					Paivi Ku	kkola					
Novartis Agent for Applicants Corporate Intellectual Property Reg. No. 50,499 One Health Plaza, Building 104 (862) 778-7875											
East Ha	nover, NJ	07936-108	30								